Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Mucosal Immunity and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CCL28 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CCL28 Recombinant Protein High purity (>95%), Endotoxin Controlled (<1.0 EU/μg). Sequence Verified. HEK293 Expressed for native glycosylation. |
View CCL28 Products |
| Gene Delivery | CCR10 Lentivirus Premade Particles Full-length ORF for stable cell line construction (GPCR internalization and chemotaxis assays). |
View CCR10 Products |
| Benchmark Ab | Anti-CCL28 Reference Antibody Recombinant positive control for assay validation. |
View CCL28 Products |
| Validator | CCL28 siRNA Set For target knockdown and specificity verification in cell-based assays. |
View CCL28 Products |
| Related Target A | CCR10 Primary GPCR receptor for CCL28; critical for mucosal homing and tumor immune evasion assays. |
View CCR10 Products |
| Related Target B | CCR3 Secondary receptor for CCL28; mediates allergic and eosinophilic inflammatory responses. |
View CCR3 Products |
| Related Target C | CCL27 Alternative CCR10 ligand; essential for specificity and cross-reactivity counter-screening. |
View CCL27 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Receptor selectivity validation (CCR10 vs. CCR3) | High-titer CCR10 and CCR3 Lentiviral Particles for robust, parallel stable cell line generation. |
| Glycosylation-dependent binding studies | HEK293-expressed recombinant CCL28 ensuring native post-translational modifications. |
| Lack of standardized positive controls | Sequence-verified clinical-grade benchmark antibody (biosimilar) available. |
| Off-target assay interference | High-purity homologous panels (CCL27) for strict specificity counter-screening. |
Live CCL28 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CCL28 therapeutics is intensifying, with major players shifting focus from traditional mucosal inflammation treatments to tumor microenvironment modulation. As first-generation therapies reach the clinic, the next wave of R&D is targeting the CCL28-CCR10 axis to overcome immune exclusion in solid tumors, particularly in colorectal, ovarian, and breast cancers where hypoxia-induced CCL28 recruits regulatory T cells (Tregs).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Neutralizing mAb | Academic/Biopharma Consortia | Inflammatory Bowel Disease (IBD), Asthma | Ligand-receptor blocking assay (Need high-purity CCL28 and stable CCR10/CCR3 cells) |
| Small Molecule Antagonists | Global Pharma / Biotech | Solid Tumors (Ovarian, Colorectal) | GPCR signaling/calcium flux assays (Need Lentivirus-driven CCR10 stable expression) |
| Bispecific Antibodies | Oncology-focused Biotechs | Tumor Immunotherapy (Treg targeting) | Dual-targeting affinity validation (Need sequence-verified CCL28 and tumor antigens) |